William Blair Has Negative Outlook of CRL FY2025 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities research analysts at William Blair dropped their FY2025 earnings estimates for Charles River Laboratories International in a report issued on Wednesday, January 15th. William Blair analyst M. Smock now anticipates that the medical research company will earn $9.40 per share for the year, down from their prior estimate of $10.59. William Blair has a “Outperform” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $10.18 per share.

A number of other analysts have also recently issued reports on CRL. Evercore ISI increased their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. Redburn Atlantic assumed coverage on shares of Charles River Laboratories International in a research note on Monday, October 14th. They issued a “sell” rating and a $151.00 price objective for the company. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective for the company. in a research note on Monday, November 18th. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Finally, Citigroup cut shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and reduced their price objective for the stock from $215.00 to $175.00 in a research note on Tuesday, October 1st. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, Charles River Laboratories International presently has an average rating of “Hold” and an average target price of $209.00.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL opened at $169.84 on Monday. The firm has a fifty day moving average price of $188.58 and a 200-day moving average price of $197.93. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The stock has a market cap of $8.69 billion, a PE ratio of 21.26, a price-to-earnings-growth ratio of 5.75 and a beta of 1.38. Charles River Laboratories International has a 1 year low of $160.85 and a 1 year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. During the same period in the prior year, the company earned $2.72 earnings per share. The firm’s revenue was down 1.6% on a year-over-year basis.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Charles River Laboratories International

Several institutional investors have recently made changes to their positions in CRL. Versant Capital Management Inc lifted its holdings in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after acquiring an additional 150 shares during the last quarter. Wolff Wiese Magana LLC bought a new stake in shares of Charles River Laboratories International in the 3rd quarter worth about $32,000. Pinnacle Bancorp Inc. lifted its holdings in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after acquiring an additional 173 shares during the last quarter. Finally, ORG Wealth Partners LLC bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth about $56,000. Institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).